I agree that this site is using cookies. You can find further informations
here
.
X
Login
My folder (
0
)
Home
About us
Home About us
Our history
Profile
Press & public relations
Friends
The library in figures
Exhibitions
Projects
Training, internships, careers
Films
Services & Information
Home Services & Information
Lending and interlibrary loans
Returns and renewals
Training and library tours
My Account
Library cards
New to the library?
Download Information
Opening hours
Learning spaces
PC, WLAN, copy, scan and print
Catalogs and collections
Home Catalogs and Collections
Rare books and manuscripts
Digital collections
Subject Areas
Our sites
Home Our sites
Central Library
Law Library (Juridicum)
BB Business and Economics (BB11)
BB Physics and Electrical Engineering
TB Engineering and Social Sciences
TB Economics and Nautical Sciences
TB Music
TB Art & Design
TB Bremerhaven
Contact the library
Home Contact the library
Staff Directory
Open access & publishing
Home Open access & publishing
Reference management: Citavi & RefWorks
Publishing documents
Open Access in Bremen
Show Desktop-Version
Toggle navigation
Signoriello, E
48
results:
OpenAccess-fulltext X
Search for persons
X
Sorted by: Relevance
Sorted by: Year
?
1
Antibody response elicited by the SARS-CoV-2 vaccine booste..:
Schiavetti I
;
Inglese M
;
Frau J
...
info:eu-repo/semantics/altIdentifier/pmid/37154406. , 2023
Link:
https://hdl.handle.net/1..
?
2
A real-world study of alemtuzumab in a cohort of Italian pa..:
Russo C. V
;
Sacca F
;
Frau J
...
info:eu-repo/semantics/altIdentifier/pmid/34558755. , 2022
Link:
http://hdl.handle.net/11..
?
3
Breakthrough SARS-CoV-2 infections in MS patients on diseas..:
Schiavetti I
;
Cordioli C
;
Stromillo M. L
...
info:eu-repo/semantics/altIdentifier/pmid/35735030. , 2022
Link:
http://hdl.handle.net/11..
?
4
Breakthrough SARS-CoV-2 infections after COVID-19 mRNA vacc..:
Sormani MP
;
Schiavetti I
;
Inglese M
...
info:eu-repo/semantics/altIdentifier/pmid/35526306. , 2022
Link:
http://hdl.handle.net/11..
?
5
Disease modifying therapies and Covid‐19 severity in Multip..:
Sormani, M. P
;
De Rossi, N
;
Schiavetti, I
...
info:eu-repo/semantics/altIdentifier/pmid/33480077. , 2021
Link:
http://hdl.handle.net/11..
?
6
Disease-Modifying Therapies and Coronavirus Disease 2019 Se..:
Sormani M. P
;
De Rossi N
;
Schiavetti I
...
info:eu-repo/semantics/altIdentifier/pmid/33480077. , 2021
Link:
http://hdl.handle.net/11..
?
7
Disease-Modifying Therapies and Coronavirus Disease 2019 Se..:
Sormani M. P
;
De Rossi N
;
Schiavetti I
...
info:eu-repo/semantics/altIdentifier/pmid/33480077. , 2021
Link:
http://hdl.handle.net/23..
?
8
Disease-Modifying Therapies and Coronavirus Disease 2019 Se..:
Sormani M. P
;
De Rossi N
;
Schiavetti I
...
info:eu-repo/semantics/altIdentifier/pmid/33480077. , 2021
Link:
https://hdl.handle.net/1..
?
9
Disease-Modifying Therapies and Coronavirus Disease 2019 Se..:
Sormani M. P
;
De Rossi N
;
Schiavetti I
...
info:eu-repo/semantics/altIdentifier/pmid/33480077. , 2021
Link:
http://hdl.handle.net/11..
?
10
Effect of SARS-CoV-2 mRNA vaccination in MS patients treate..:
Sormani M. P
;
Schiavetti I
;
Carmisciano L
...
info:eu-repo/semantics/altIdentifier/pmid/34563483. , 2021
Link:
https://hdl.handle.net/1..
?
11
Effect of SARS-CoV-2 mRNA vaccination in MS patients treate..:
Sormani MP
;
Inglese M
;
Schiavetti I
...
info:eu-repo/semantics/altIdentifier/pmid/34563483. , 2021
Link:
http://hdl.handle.net/11..
?
12
Exit Strategies in Natalizumab-Treated RRMS at High Risk of..:
Zanghi A
;
Gallo A
;
Avolio C
...
info:eu-repo/semantics/altIdentifier/pmid/33844155. , 2021
Link:
http://hdl.handle.net/11..
?
13
Effect of SARS-CoV-2 mRNA vaccination in MS patients treate..:
Sormani M. P
;
Schiavetti I
;
Carmisciano L
...
info:eu-repo/semantics/altIdentifier/pmid/34563483. , 2021
Link:
http://hdl.handle.net/11..
?
14
Exit Strategies in Natalizumab-Treated RRMS at High Risk of..:
Zanghi A
;
Gallo A
;
Avolio C
...
info:eu-repo/semantics/altIdentifier/wos/WOS:000639643100002. , 2021
Link:
http://hdl.handle.net/11..
?
15
Exit Strategies in Natalizumab-Treated RRMS at High Risk of..:
Zanghi A
;
Gallo A
;
Avolio C
...
info:eu-repo/semantics/altIdentifier/wos/WOS:000639643100002. , 2021
Link:
http://hdl.handle.net/11..
1-15
